An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

TODAY i have some great news to share. Besides the fact that last week was the King's Birthday, something exciting was happening in the HIV ...

EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

The results suggest the possibility of a vaccine for HIV/AIDS, which killed more than half a million people last year.

The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...

Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative to daily pills and addressing the needs of key populations.

Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...

Lenacapavir, a long-acting HIV capsid inhibitor that could potentially be given every six months, continues to show good viral suppression, both in people starting antiretroviral therapy for the first ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Subcutaneous lenacapavir in combination with an optimized background regimen led to sustained virologic suppression in 81% of heavily treated people with HIV at week 26, data from an ongoing phase ...